Solid Biosciences (SLDB) Notes Payables (2024 - 2026)

Solid Biosciences has reported Notes Payables for 3 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Notes Payables fell 30.21% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 30.21% YoY) and the FY2025 annual result came in at $9.2 million, up 192.06% from the prior year.
• Notes Payables retreated to $3.4 million in Q1 2026 per SLDB's latest filing, from $9.2 million in the prior quarter.
• Over five years, Notes Payables peaked at $9.2 million in Q4 2025 and troughed at $3.2 million in Q4 2024.
• A 3-year average of $5.2 million and a median of $4.8 million in 2025 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2025 and 2026: Notes Payables jumped 192.06% in 2025, then tumbled 30.21% in 2026.
• Over 3 years, Notes Payables stood at $3.2 million in 2024, then soared by 192.06% to $9.2 million in 2025, then tumbled by 63.59% to $3.4 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $3.4 million, $9.2 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.